Skip to main content
. 2014 Dec 3;89(4):2157–2169. doi: 10.1128/JVI.02092-14

FIG 4.

FIG 4

wt RABV (or the glycoprotein from wt RABV) does not inhibit LPS-mediated DC activation. (A) Quantitative assessment of CD86, CD80, and MHC-II expression in DCs infected with RABVs left untreated or treated with the indicated concentration of LPS. (B) Analysis of DC viability after infection with RABVs at 10 gene copy numbers/cell using trypan blue.